VahatiCor Closes Oversubscribed Series B Financing to Accelerate A-FLUX® Development for Coronary Microvascular Dysfunction.

VahatiCor
Written By Kathryn Deebel

About VahatiCor

VahatiCor, Inc., a T45 Labs portfolio company, develops innovative medical technology solutions for patients with Coronary Microvascular Dysfunction (CMD), a debilitating condition affecting millions of people who experience chest pain despite having no blockages in their major coronary arteries. The A-FLUX Reducer System® introduces a new therapeutic pathway for patients affected by coronary microvascular dysfunction (CMD), a condition that can cause chest pressure, heaviness, and discomfort. Through this advancement, VahatiCor is helping broaden access to care for individuals who have long faced limited treatment alternatives.

Kathryn Deebel
Previous

SAI360 Announces Acquisition of Plural Policy, Expanding AI Compliance Capabilities to Accelerate Regulatory Change Management
Next

E2 (Endovascular Engineering, Inc) Presents ENGULF Pivotal Study as a Late-Breaking Clinical Trial at the VIVA Conference